Related references
Note: Only part of the references are listed.Usability of mepolizumab single-use prefilled syringe for patient self-administration
Elisabeth H. Bel et al.
JOURNAL OF ASTHMA (2020)
Impact of pain associated with the subcutaneous administration of adalimumab
Cristina Gely et al.
GASTROENTEROLOGIA Y HEPATOLOGIA (2020)
Immunogenicity of Biosimilars for Rheumatic Diseases, Plaque Psoriasis, and Inflammatory Bowel Disease: A Review from Clinical Trials and Regulatory Documents
Vibeke Strand et al.
BIODRUGS (2020)
ECCO Guidelines on Therapeutics in Crohn's Disease: Medical Treatment
Joana Torres et al.
JOURNAL OF CROHNS & COLITIS (2020)
Injection Site Reactions in the Federal Adverse Event Reporting System (FAERS) Post-Marketing Database Vary Among Biologics Approved to Treat Moderate-To-Severe Psoriasis
Elsie Grace et al.
DERMATOLOGY AND THERAPY (2020)
Phase 3 randomized, placebo-controlled study of galcanezumab in patients with chronic cluster headache: Results from 3-month double-blind treatment
David W. Dodick et al.
CEPHALALGIA (2020)
Classification and mitigation of negative injection experiences with biologic medications
Jennifer M. Fernandez et al.
DERMATOLOGIC THERAPY (2020)
Adherence to subcutaneous anti-TNFα agents in patients with rheumatoid arthritis is largely influenced by pain and skin sensations at the injection site
Fausto Salaffi et al.
INTERNATIONAL JOURNAL OF RHEUMATIC DISEASES (2020)
P620 Maintenance of clinical remission with SB5 biosimilar after switch from adalimumab originator: Real-life experience of a tertiary referral centre
G Dragoni et al.
Journal of Crohns & Colitis (2020)
P505 Different failure rates after non-medical switching of 744 patients from adalimumab originator to 2 different adalimumab biosimilars at Cambridge University Hospitals, UK: real-world experience
D Rosembert et al.
Journal of Crohns & Colitis (2020)
P473 Long-term follow-up of switching from original adalimumab to adalimumab biosimilar: real-world data in IBD
C Padilla Suarez et al.
Journal of Crohns & Colitis (2020)
Pathophysiology, Clinical Presentation, and Treatment of Psoriasis A Review
April W. Armstrong et al.
JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION (2020)
A portfolio of biologic self-injection devices in rheumatology: how patient involvement in device design can improve treatment experience
Bart J. F. van den Bemt et al.
DRUG DELIVERY (2019)
Joint AAD-NPF guidelines of care for the management and treatment of psoriasis with biologics
Alan Menter et al.
JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY (2019)
Patient and physician preferences for attributes of biologic medications for severe asthma
Heather L. Gelhorn et al.
PATIENT PREFERENCE AND ADHERENCE (2019)
Subcutaneous Injection of Drugs: Literature Review of Factors Influencing Pain Sensation at the Injection Site
Iris Usach et al.
ADVANCES IN THERAPY (2019)
Usability and safety of SB5 (an adalimumab biosimilar) prefilled syringe and autoinjector in patients with rheumatoid arthritis
Jeehoon Ghil et al.
CURRENT MEDICAL RESEARCH AND OPINION (2019)
Injectability as a function of viscosity and dosing materials for subcutaneous administration
Russell P. Watt et al.
INTERNATIONAL JOURNAL OF PHARMACEUTICS (2019)
Role of biological agents in treatment of rheumatoid arthritis
Shing T. Law et al.
PHARMACOLOGICAL RESEARCH (2019)
Decreased Injection Site Pain Associated with Phosphate-Free Etanercept Formulation in Rheumatoid Arthritis or Psoriatic Arthritis Patients: A Randomized Controlled Trial
Stanley Cohen et al.
RHEUMATOLOGY AND THERAPY (2019)
Patients beliefs on intravenous and subcutaneous routes of administration of biologics for severe asthma treatment: A cross-sectional observational survey study
Pierachille Santus et al.
WORLD ALLERGY ORGANIZATION JOURNAL (2019)
Comparison of injection-site reactions between the etanercept biosimilar SB4 and the reference etanercept in patients with rheumatoid arthritis from a phase III study
G. Girolomoni et al.
BRITISH JOURNAL OF DERMATOLOGY (2018)
P497 Injection site reactions and injection site pain for the adalimumab biosimilar ABP 501: Results from two double-blind, randomised, controlled studies
E Krishnan et al.
Journal of Crohns & Colitis (2018)
Buffered local anesthetics reduce injection pain and provide anesthesia for up to 5 hours
Josefine Bunke et al.
JOURNAL OF PLASTIC RECONSTRUCTIVE AND AESTHETIC SURGERY (2018)
Pain Catastrophizing, Subjective Outcomes, and Inflammatory Assessments Including Ultrasound: Results From a Longitudinal Study of Rheumatoid Arthritis Patients
Hilde B. Hammer et al.
ARTHRITIS CARE & RESEARCH (2018)
Preference for a prefilled syringe or an auto-injection device for delivering golimumab in patients with moderate-to-severe ulcerative colitis: a randomized crossover study
Severine Vermeire et al.
PATIENT PREFERENCE AND ADHERENCE (2018)
Subcutaneous Administration of Biotherapeutics: An Overview of Current Challenges and Opportunities
Beate Bittner et al.
BIODRUGS (2018)
The nocebo effect: a clinical challenge in the era of biosimilars
Lieven Pouillon et al.
EXPERT REVIEW OF CLINICAL IMMUNOLOGY (2018)
Are Injection Site Reactions in Monoclonal Antibody Therapies Caused by Polysorbate Excipient Degradants?
Satish K. Singh et al.
JOURNAL OF PHARMACEUTICAL SCIENCES (2018)
Comparison between prefilled syringe and autoinjector devices on patient-reported experiences and pharmacokinetics in galcanezumab studies
Virginia L. Stauffer et al.
PATIENT PREFERENCE AND ADHERENCE (2018)
Evaluation of psychological resistance to insulin treatment in type II diabetic patients
Armaghan Moravej Aleali et al.
DIABETES & METABOLIC SYNDROME-CLINICAL RESEARCH & REVIEWS (2018)
Non-pharmacological Effects in Switching Medication: The Nocebo Effect in Switching from Originator to Biosimilar Agent
Lars Erik Kristensen et al.
BIODRUGS (2018)
GP2015, a proposed etanercept biosimilar: Pharmacokinetic similarity to its reference product and comparison of its autoinjector device with prefilled syringes
Oliver von Richter et al.
BRITISH JOURNAL OF CLINICAL PHARMACOLOGY (2017)
Growth hormone delivery devices: current features and potential for enhanced treatment adherence
Tilman R. Rohrer et al.
EXPERT OPINION ON DRUG DELIVERY (2017)
Comparative usability study for a certolizumab pegol autoinjection device in patients with rheumatoid arthritis
Barbara Domanska et al.
EXPERT OPINION ON DRUG DELIVERY (2017)
Old and New Biological Therapies for Psoriasis
Kirsten Ronholt et al.
INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES (2017)
Third European Evidence-based Consensus on Diagnosis and Management of Ulcerative Colitis. Part 2: Current Management
Marcus Harbord et al.
JOURNAL OF CROHNS & COLITIS (2017)
Chronic Disease and Self-Injection: Ethnographic Investigations into the Patient Experience During Treatment
Michael Schiff et al.
RHEUMATOLOGY AND THERAPY (2017)
EULAR recommendations for the management of rheumatoid arthritis with synthetic and biological disease-modifying antirheumatic drugs: 2016 update
Josef S. Smolen et al.
ANNALS OF THE RHEUMATIC DISEASES (2017)
Comparison of the pharmacokinetics, safety, and immunogenicity of MSB11022, a biosimilar of adalimumab, with Humira® in healthy subjects
Elizabeth Hyland et al.
BRITISH JOURNAL OF CLINICAL PHARMACOLOGY (2016)
Subcutaneous Injection Volume of Biopharmaceuticals-Pushing the Boundaries
Roman Mathaes et al.
JOURNAL OF PHARMACEUTICAL SCIENCES (2016)
2015 American College of Rheumatology Guideline for the Treatment of Rheumatoid Arthritis
Jasvinder A. Singh et al.
ARTHRITIS & RHEUMATOLOGY (2016)
Randomized Crossover Comparison of Injection Site Pain with 40 mg/0.4 or 0.8mL Formulations of Adalimumab in Patients with Rheumatoid Arthritis
Peter Nash et al.
RHEUMATOLOGY AND THERAPY (2016)
The Patient's Guide to Psoriasis Treatment. Part 3: Biologic Injectables
Michael Abrouk et al.
DERMATOLOGY AND THERAPY (2016)
Tolerability of High-Volume Subcutaneous Injections of a Viscous Placebo Buffer: A Randomized, Crossover Study in Healthy Subjects
Clapton Dias et al.
AAPS PHARMSCITECH (2015)
Simple Psychological Interventions for Reducing Pain From Common Needle Procedures in Adults
Katelynn E. Boerner et al.
CLINICAL JOURNAL OF PAIN (2015)
Tolerability of hypertonic injectables
Wei Wang
INTERNATIONAL JOURNAL OF PHARMACEUTICS (2015)
Reasons for discontinuation of subcutaneous biologic therapy in the treatment of rheumatoid arthritis: a patient perspective
Susan C. Bolge et al.
PATIENT PREFERENCE AND ADHERENCE (2015)
Belimumab for Systemic Lupus Erythematosus: A Cochrane Systematic Review and MetaAnalysis
Jasvinder A. Singh et al.
ARTHRITIS & RHEUMATOLOGY (2015)
GLACIER: An open-label, randomized, multicenter study to assess the safety and tolerability of glatiramer acetate 40 mg three-times weekly versus 20 mg daily in patients with relapsing-remitting multiple sclerosis
Jerry S. Wolinsky et al.
MULTIPLE SCLEROSIS AND RELATED DISORDERS (2015)
Biologics in inflammatory bowel disease: what are the data?
Justin Cote-Daigneault et al.
UNITED EUROPEAN GASTROENTEROLOGY JOURNAL (2015)
Impact of injection speed and volume on perceived pain during subcutaneous injections into the abdomen and thigh: a single-centre, randomized controlled trial
T. Heise et al.
DIABETES OBESITY & METABOLISM (2014)
The role of excess subcutaneous fat in pain and sensory sensitivity in obesity
R. C. Price et al.
EUROPEAN JOURNAL OF PAIN (2013)
Educational session as a tool to increase patient satisfaction of switching etanercept from the prefilled syringe to the autoinjection pen
Joaquin Borras-Blasco et al.
EXPERT OPINION ON BIOLOGICAL THERAPY (2013)
Selective TNF-α inhibitor-induced injection site reactions
Giuseppe Murdaca et al.
EXPERT OPINION ON DRUG SAFETY (2013)
Comparative injection-site pain and tolerability of subcutaneous serum-free formulation of interferonβ-1a versus subcutaneous interferonβ-1b: results of the randomized, multicenter, Phase IIIb REFORMS study
Barry Singer et al.
BMC NEUROLOGY (2012)
An open-label, multicenter study to evaluate the safe and effective use of the single-use autoinjector with an Avonex® prefilled syringe in multiple sclerosis subjects
J. Theodore Phillips et al.
BMC NEUROLOGY (2011)
Injection-site burning and stinging in patients with rheumatoid arthritis using injectable biologics
Jeffrey R. Curtis et al.
CURRENT MEDICAL RESEARCH AND OPINION (2011)
Assessment of self-injection experience in patients with rheumatoid arthritis: psychometric validation of the Self-Injection Assessment Questionnaire (SIAQ)
Dorothy Keininger et al.
HEALTH AND QUALITY OF LIFE OUTCOMES (2011)
Judging Pain Sensitivity with Subcutaneous Lidocaine Injections
Eileen R. Manabat et al.
PAIN MEDICINE (2011)
Tolerability and safety of novel half milliliter formulation of glatiramer acetate for subcutaneous injection: an open-label, multicenter, randomized comparative study
G. Anderson et al.
JOURNAL OF NEUROLOGY (2010)
A systematic review of measures for reducing injection pain during adult immunization
Mary-Ellen Hogan et al.
VACCINE (2010)
Underappreciated medication contraindication
Alicia J. Zbehlik et al.
ARTHRITIS CARE & RESEARCH (2010)
A randomised, cross-over study comparing injection site pain with subcutaneous epoetin beta and subcutaneous darbepoetin alfa in patients with chronic kidney disease
Simon D. Roger et al.
CURRENT MEDICAL RESEARCH AND OPINION (2008)
Are there differences in immunogenicity and safety of vaccines according to the injection method?
F. Ajana et al.
MEDECINE ET MALADIES INFECTIEUSES (2008)
Adalimumab for maintenance of clinical response and remission in patients with Crohn's disease: The CHARM trial
Jean-Frederic Colombel et al.
GASTROENTEROLOGY (2007)
Immune-mediated inflammatory diseases (IMIDs) and biologic therapy: a medical revolution
Annabel Kuek et al.
POSTGRADUATE MEDICAL JOURNAL (2007)
Increased injection pain with darbepoetin-α compared to epoetin-β in paediatric dialysis patients
Claus Peter Schmitt et al.
NEPHROLOGY DIALYSIS TRANSPLANTATION (2006)
Clinical assessment of pain, tolerability, and preference of an autoinjection pen versus a prefilled syringe for patient self-administration of the fully human, monoclonal antibody adalimumab: The TOUCH trial
Alan Kivitz et al.
CLINICAL THERAPEUTICS (2006)
Clinical response to alimumab treatment in patients with moderate to severe psoriasis: Double-blind, randomized controlled trial and open-label extension study
Kenneth B. Gordon et al.
JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY (2006)
Effects of subcutaneous administration of glutamate on pain, sensitization and vasomotor responses in healthy men and women
Parisa Gazerani et al.
PAIN (2006)
Pain following controlled cutaneous insertion of needles with different diameters
Lars Arendt-Nielsen et al.
SOMATOSENSORY AND MOTOR RESEARCH (2006)
Fear of injections in young adults: Prevalence and associations
Y Nir et al.
AMERICAN JOURNAL OF TROPICAL MEDICINE AND HYGIENE (2003)
Effects of injection duration on site-pain intensity and bruising associated with subcutaneous heparin
H Chan
JOURNAL OF ADVANCED NURSING (2001)
Drawing up and administering intramuscular injections: a review of the literature
MA Rodger et al.
JOURNAL OF ADVANCED NURSING (2000)
Share Paper
